Transcatheter Cardiovascular Therapeutics

SURTAVI: TAVR Results Similar to Surgery at 5 Years

November 06, 2021

Results of the 5-year follow-up from SURTAVI, which were presented at TCT 2021, provide insight into the associations of TAVR with mortality and stroke compared to SAVR in patients with severe aortic stenosis considered to be at intermediate risk.

FFR-Guided PCI Fails to Prove Noninferiority to CABG in FAME 3

November 04, 2021

Data from the FAME 3 trial cast doubt on the role of FFR-guided PCI versus CABG among patients with 3-vessel coronary artery disease.

Tsuyoshi Kaneko, MD: Perspective on TAVR Data at TCT Connect 2020

October 20, 2020

Practical Cardiology advisory board member Tsuyoshi Kaneko, MD, reflects on 3 studies examining topics related to TAVR from late-breaking sessions at TCT Connect 2020.

ACURATE neo Valve Fails to Demonstrate NonInferiority vs CoreValve Evolut in SCOPE II

October 19, 2020

Results of the SCOPE II trial from TCT Connect offer insight into the head-to-head comparison of ACURATE neo valve versus the CoreValve Evolut R System.

REDUCE-IT PCI Details Benefits of Icosapent Ethyl in Patients with History of PCI

October 18, 2020

Results of REDUCE-IT PCI detail a 34% reduction in 5-point MACE and a 39% reduction in total events among patients receiving icosapent ethyl (Vascepa) in the original trial with a history of PCI.

ULTIMATE Details 3-Year Benefit of IVUS-Guided PCI vs Angiography-Guided PCI

October 16, 2020

Results from 3-year follow-up of the ULTIMATE study indicate IVUS-guided PCI was associated with lower rates of TVF and stent thrombosis.

Crushed Prasugrel Prior to PCI Provides No Reperfusion Benefit in STEMI Patients

October 15, 2020

A trial presented at TCT 2020 suggests crushed prasugrel provided no reperfusion benefit when compared against integral tablet in STEMI patients.